Skip to content

The Natural History of Danon Disease

The Natural History of Danon Disease

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03766386
Enrollment
200
Registered
2018-12-06
Start date
2018-11-30
Completion date
2024-11-30
Last updated
2022-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Danon Disease

Brief summary

Danon disease (DD) is a rare, X-linked disorder associated with severe cardiomyopathy, and in many cases, skeletal myopathy, and cognitive impairment caused by mutations in the LAMP2 gene. There is still uncertainty regarding the natural history of DD because of its rarity. This study aims to determine the natural history of DD through the collection and analysis of retrospective and prospective data. To achieve this, the investigators will perform surveys and obtain medical records from DD patients. The same cohort of patients will also be assessed by a multidisciplinary team with expertise in DD (cardiologist, neurologist, ophthalmologist, psychologist, geneticist) at the University of California, San Diego. All patients with DD are eligible, including those who underwent a heart transplant. Additionally, data and records from deceased patients will provide valuable retrospective data for this study.

Detailed description

The study design will include: 1. Collection of information for all patients from: * Survey of patient or caregiver (if the patient has deceased) * Medical Charts 2. Collection of information from living patients assessed by the multidisciplinary team at the University of California, San Diego including: * A complete medical history and physical examination * Cardiac Testing (Electrocardiography; Echocardiography; Cardiac magnetic resonance imaging with gadolinium contrast agent-gadolinium contrast is optional-; Cardiopulmonary Test) * Pulmonary function testing (PFT) * Neuromuscular Assessment * Cognitive Tests * Vision exam including retinal evaluation * Laboratory Tests * Questionnaires on Quality of life * Needle Skeletal muscle biopsy (only for patients over 18 years old) * Abdominal Ultrasound for assessment of the liver structure

Interventions

None listed

Sponsors

Rocket Pharmaceuticals Inc.
CollaboratorINDUSTRY
University of California, San Diego
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
0 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

• Living or deceased patients with a diagnosis of Danon disease(including patients who may or may not have undergone heart transplantation) based on a genetic test positive for the LAMP2 mutation

Exclusion criteria

• Patients without a genetic test positive for a LAMP2 mutation

Design outcomes

Primary

MeasureTime frameDescription
Cardiac structure over time6, 12, 18, 24, 30, 36 monthsChange of cardiac structure (wall thickness -mm) measured by cardiac ultrasound / cardiac magnetic resonance

Countries

United States

Contacts

Primary ContactEric Adler, MD
eradler@ucsd.edu8582462996

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026